Michael T. Hemann

Michael T. Hemann

Associate Professor of Biology

Michael T. Hemann uses mouse models to combat cancers resistant to chemotherapy.





Ryan Hayman



Assistant Phone


  • PhD, 2001, Johns Hopkins University
  • BS, 1993, Molecular Biology and Biochemistry, Wesleyan University

Research Summary

Many human cancers do not respond to chemotherapy, and often times those that initially respond eventually acquire drug resistance. Our lab uses high-throughput screening technology — combined with murine stem reconstitution and tumor transplantation systems — to investigate the genetic basis for this resistance. Our goal is to identify novel cancer drug targets, as well as strategies for tailoring existing cancer therapies to target the vulnerabilities associated with specific malignancies.

Key Publications

  1. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Zhao, B, Sedlak, JC, Srinivas, R, Creixell, P, Pritchard, JR, Tidor, B, Lauffenburger, DA, Hemann, MT. 2016. Cell 165, 234-246.
    doi: 10.1016/j.cell.2016.01.045PMID:26924578
  2. DNA damage-mediated induction of a chemoresistant niche. Gilbert, LA, Hemann, MT. 2010. Cell 143, 355-66.
    doi: 10.1016/j.cell.2010.09.043PMID:21029859
  3. The combined status of ATM and p53 link tumor development with therapeutic response. Jiang, H, Reinhardt, HC, Bartkova, J, Tommiska, J, Blomqvist, C, Nevanlinna, H, Bartek, J, Yaffe, MB, Hemann, MT. 2009. Genes Dev 23, 1895-909.
    doi: 10.1101/gad.1815309PMID:19608766
  4. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Hemann, MT, Bric, A, Teruya-Feldstein, J, Herbst, A, Nilsson, JA, Cordon-Cardo, C, Cleveland, JL, Tansey, WP, Lowe, SW. 2005. Nature 436, 807-11.
    doi: 10.1038/nature03845PMID:16094360
  5. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Hemann, MT, Fridman, JS, Zilfou, JT, Hernando, E, Paddison, PJ, Cordon-Cardo, C, Hannon, GJ, Lowe, SW. 2003. Nat Genet 33, 396-400.
    doi: 10.1038/ng1091PMID:12567186

Recent Publications

  1. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. Vassel, FM, Bian, K, Walker, GC, Hemann, MT. 2020. Proc Natl Acad Sci U S A 117, 28922-28924.
    doi: 10.1073/pnas.2016067117PMID:33144509
  2. Integrated regulatory models for inference of subtype-specific susceptibilities in glioblastoma. Liu, Y, Shi, N, Regev, A, He, S, Hemann, MT. 2020. Mol Syst Biol 16, e9506.
    doi: 10.15252/msb.20209506PMID:32974985
  3. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Dalin, S, Sullivan, MR, Lau, AN, Grauman-Boss, B, Mueller, HS, Kreidl, E, Fenoglio, S, Luengo, A, Lees, JA, Vander Heiden, MG et al.. 2019. Cancer Res 79, 5723-5733.
    doi: 10.1158/0008-5472.CAN-19-0960PMID:31484670
  4. Functional screens identify coordinators of RNA molecule birth, life, and death as targetable cancer vulnerabilities. Braun, CJ, Hemann, MT. 2019. Curr Opin Genet Dev 54, 105-109.
    doi: 10.1016/j.gde.2019.04.003PMID:31121413
  5. In vivo RNAi screening identifies as a target for combination therapy with TKIs in BCP-ALL. Fiedler, ERC, Bhutkar, A, Lawler, E, Besada, R, Hemann, MT. 2018. Blood Adv 2, 1229-1242.
    doi: 10.1182/bloodadvances.2017015610PMID:29853524
  6. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer. Ramos, A, Hemann, MT. 2017. Cell 170, 411-413.
    doi: 10.1016/j.cell.2017.07.018PMID:28753421
  7. PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Soto-Feliciano, YM, Bartlebaugh, JME, Liu, Y, Sánchez-Rivera, FJ, Bhutkar, A, Weintraub, AS, Buenrostro, JD, Cheng, CS, Regev, A, Jacks, TE et al.. 2017. Genes Dev 31, 973-989.
    doi: 10.1101/gad.295857.117PMID:28607179
  8. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Bruno, PM, Liu, Y, Park, GY, Murai, J, Koch, CE, Eisen, TJ, Pritchard, JR, Pommier, Y, Lippard, SJ, Hemann, MT et al.. 2017. Nat Med 23, 461-471.
    doi: 10.1038/nm.4291PMID:28263311
  9. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Bent, EH, Gilbert, LA, Hemann, MT. 2016. Genes Dev 30, 1811-21.
    doi: 10.1101/gad.284851.116PMID:27566778
  10. Rewiring the solid tumor epigenome for cancer therapy. Braun, CJ, Hemann, MT. 2016. Expert Rev Anticancer Ther 16, 977-87.
    doi: 10.1080/14737140.2016.1212663PMID:27410491
More Publications


Photo credit: Bryce Vickmark